Skip to main content
Premium Trial:

Request an Annual Quote

ChromoCure, GRG Ink Cancer Treatment Monitoring Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ChromoCure today said that it will collaborate with Genome Research Group in developing technologies for monitoring and determining the efficacy of cancer treatments.

Under the agreement, ChromoCure said that it will have access to GRG's therapeutic modeling protocols and algorithms that use hypothermic modulation and resonance for the non-toxic and non-invasive treatment of cancer. In return, GRG will have access to ChromoCure's chromosomal scanner technology, which includes a series of systems, processes, cell preparation techniques, and diagnostic algorithms.

ChromoCure's systems measure aneuploidy to detect cancer and measure cancer progression. The Reno, Nev.-based firm claims that its scanner is has a 100 percent accuracy rate.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more